Biotech Daily Home

Biotech Daily covers the major announcements from ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A940 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

The website is best viewed with the Firefox browser.

Download subscription form here



Latest News !


Teva Returns Mesoblast Heart Drug; Equity Facility - Jun 14, 2016

Biotech Daily Policy On Mega-Day-Traders - May 3, 2016

Budget 2016: Not Much For Biotech, Innovation
- Details, Comment - May 3, 4, 2016

NHMRC $3.3m For Windfarm Health Impacts
AMA Position, Biotech Daily Comment - Mar 22, 2016

2015 - The Year In Review

PM Malcolm Turbull Launches $1.1b Innovation, Science Agenda
Comment - Dec 7, 8, 2015

Novartis Buys Spinifex For $916m

Genetic Technologies Dr Mervyn Jacobson 12 Months Gaol

Gaol For The Phosphagenics Three: Dr Esra Ogru
Dr Robert Gianello, Dr Woei-Jia Jiang

BRIL Group Senate Innovation Submission:
Set Aside 25% Of $20bn MRFF For Commercialization


May BDI-40 Up 3%
ASX200 Up 2%, Big Caps Up 10%

Cellmid Up 32%, Psivida 26%; Anteo Down 27%, Avita 22%

Ellex, Polynovo promoted into BDI-20

June 1, 2016
The Biotech Daily Top 40 Index (BDI-40) climbed 3.2 percent in May to a collective market capitalization of $7,670 million, with the S&P ASX200 up 2.4 percent to 5,379 points.
For the year to May 31, 2016, the BDI-40 (which does not include the three Big Caps of Cochlear, CSL and Resmed) climbed 19.6 percent while the ASX200 fell 5.8 percent.
The three Big Caps climbed a collective 10.0 percent, with Cochlear and CSL hitting their record high market capitalizations. Cochlear was up 11.7 percent to $6,903 million, CSL climbed 10.0 percent to $52,961 million, with Resmed up 9.1 percent to $11,398 million. For the year to May 31, 2016, the Big Caps were up a collective 21.1 percent.
Twenty-three of the BDI-40 companies were up, 15 fell and two were unchanged, with 12 companies up more than 10 percent and five down more than 10 percent.
Cellmid was the best, up $6 million or 31.6 percent to $25 million, Psivida was up 25.7 percent to $176 million and Ellex climbed up 25.0 percent to $115 million, followed by Acrux (17.6%), Viralytics (17.5%), Antisense (16.7%), Factor Therapeutics (Tissue Therapies) (13.6%), Nanosonics (13.2%) and Genetic Technologies (11.8%).
Anteo led the falls, down $17 million or 27.4 percent to $45 million, followed by Avita down 22.2 percent to $56 million, Atcor (21.2%), IDT (16.9%) and Neuren (16.1%).
The Nasdaq Biotech Index was up 4.2 percent in May, but down 23.5 percent for the 12 months, with former ASX companies Heartware down 7.4 percent to $712 million, Aviragen (Biota) down 2.5 percent to $79 million and Sunshine Heart recovering 5.9 percent to $18 million.
Outside the BDI-40, Resapp climbed a further 63.3 percent to $178 million, $176 million above the June 2015 $4 million recapitalization of Narhex. Unilife lost $46 million or 36.2 percent to $81 million in May and $340 million or 80.8 percent for the 12 months.
Ellex and Polynovo have performed strongly and will be promoted into the BDI-20, swapping places with Biotron and Osprey, which join the Second 20.
BDI-40 v S&P ASX200 Jun 30, 2006 to May 31, 2016 – Adjusted
BDI-40 v S&P ASX200 May 31, 2015 to May 31, 2016 
Big Caps (Cochlear, CSL, Resmed) May 31, 2015 to May 31, 2016


 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At May 31, 2016



* Biotech Daily editor, David Langsam, owns shares in Acrux, Admedus, Benitec, Mesoblast
   Nanosonics, Neuren and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: